Back to School: How biopharma can reboot drug development. Access exclusive analysis here

D-Amphetamine Transdermal System: Phase II data

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary reported top-line data from a double-blind, crossover,

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE